SCHEDULE: Wellington Management Discloses 3.55% Stake in Charles River

Wellington Management Group and its affiliates reported a 3.55% beneficial ownership stake in Charles River Laboratories International, Inc. common stock as of December 31, 2025.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP filed an Amendment No. 3 to Schedule 13G.
• The filing reports beneficial ownership of common stock in Charles River Laboratories International, Inc. (CUSIP: 159864107).
• As of December 31, 2025, the aggregate amount beneficially owned by the reporting persons is 1,749,213 shares.
• This represents 3.55% of the class of Charles River Laboratories International, Inc. common stock.
• The reporting persons hold shared voting power over 1,404,878 shares and shared dispositive power over 1,749,213 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine regulatory disclosure of beneficial ownership by an institutional investor and does not contain new operational or financial performance information about the issuer.

Positives

• The filing confirms a significant, passive institutional investment by Wellington Management, indicating a vote of confidence in Charles River Laboratories International, Inc. by a major asset manager.

Negatives

• No specific negative information regarding Charles River Laboratories International, Inc. is disclosed in this ownership filing.

Risks

• No specific risks related to Charles River Laboratories International, Inc. are disclosed in this ownership filing.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Charles River Laboratories International, Inc.'s future performance or strategic direction.

Management Comments

• The filing includes a certification from Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant holdings by major asset managers. Wellington Management's stake in Charles River Laboratories International, Inc. reflects its investment strategy within the life sciences and contract research organization (CRO) sector, a segment often characterized by strong demand for drug discovery and development services.

Comparison to Industry Standards

• This Schedule 13G filing is a regulatory disclosure of beneficial ownership and does not contain information suitable for direct comparison to industry-specific performance benchmarks or competitor results.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing market perception of institutional confidence.

Next Steps

• Future amendments to this Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

Charles River Laboratories, CRL, Wellington Management, Institutional Ownership, Schedule 13G, Common Stock, Investment, Beneficial Ownership